Please login to the form below

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy.

With a team that includes some of the world’s leading market access and pricing experts, clients across the globe turn to us for innovative pricing, market access and value communication strategies through the full product development cycle.

Proud winners of the Queen’s Award for Enterprise: International Trade, we aim to offer world-class solutions that continue to drive growth for our global clients.

www.validinsight.com

Areas of Expertise

Valid Insight is an award winning specialist global market access consultancy firm. Our team are experts in understanding the global payer environment and can help you overcome the evolving market access challenges at any stage in the product lifecycle.

From determining the right strategy for you to stay competitive in your market, to helping you create a compelling and powerful value proposition, to empowering you with the latest marketplace tools and assisting you in developing your current team to help them realise their full potential, Valid Insight can be your trusted partner, and so much more.

Press Releases

Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019

For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress

The Valid Insight visit to Buckingham Palace

In April, it was announced that the Valid Insight team had been awarded the Queen’s Award for Enterprise in International Trade. It was an amazing moment for us all. It was not only a testament to the team’s hard work and indisputable expertise, but to our clients’ trust in us to help them to keep advancing patient access to medicines.

Valid Insight wins the Queen’s Most Coveted Award for Enterprise

Valid Insight, a leading pharmaceutical global market access consultancy, is one of a select number of businesses to win the esteemed Queen's Award for Enterprise: International Trade.

White Papers and Resources

The 'winner takes all' pricing game

Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.

RWE Blog 4: The place of real-world evidence in the market access strategy

The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.

RWE Blog 3: Is real-world evidence the holy grail

We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.

RWE Blog 2: Payers use real-world data cautiously

Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.

RWE Blog 1: Real-world challenges and real-world data

This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.

Valid News, Market Access Insights, Issue 3

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published the 21st edition of the EML, recommending the inclusion of 28 new medicines.

Confidential contracting – the road to flexible pricing

Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.

White paper for download: The vicious circle of pharmaceutical tendering

In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.

Innovative pricing and contracting options

With rising treatment prices and healthcare spending, payer organisations are making efforts to contain costs.

White paper for download: Real-world evidence: Hurdles and the holy grail

Real-world evidence and real-world data is a hot topic in market access today. Conferences, publications and studies are all focussing on the opportunities and benefits they bring. It’s also becoming a big area of investment for pharma, biotech and life science companies.

Videos and Podcasts

Latest Tweets

Awards

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.
Valid Insight
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.
Valid Insight
RWE Blog 2: Payers use real-world data cautiously
Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
RWE Blog 1: Real-world challenges and real-world data
This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight
Valid News, Market Access Insights, Issue 3
Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.
Valid Insight